BioNTech tests new cancer drugs in patients out of options
NCT ID NCT07147348
Summary
This early-stage study is testing the safety and initial effectiveness of two new cancer drugs, BNT3212 alone and combined with BNT327. It is for adults with advanced solid tumors who have no other standard treatments left. The main goals are to find safe doses and see if the drugs can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Scientia Clinical Research Limited
NOT_YET_RECRUITINGRandwick, 2031, Australia
-
Shanghai East Hospital
RECRUITINGShanghai, 200120, China
Conditions
Explore the condition pages connected to this study.